Prenatal and New-born Genetic Testing Market |Leading Key Players: Ariosa Diagnostics (Roche), Berry Genomics, BGI, Biorad

Market Overview and Growth Factors:

Prenatal and new-born genetic testing market will show stable growth in the upcoming years due to increasing prevalence of genetic disorders and chromosomal anomalies that has resulted in demand for prenatal and newborn screening for early detection of birth defects.  As per CDC, birth defects occur in about 3% of the total live births across the world, leading to infant death.

Increasing benefits and technological advancements in the field of infant genetic testing will drive the prenatal and new-born genetic testing market. Increase in adoption of new technologies such as non-invasive prenatal testing (NIPT) and non-invasive cell-free fetal DNA-based screening in the developed regions of America, for early detection of births defects will foster market growth opportunities. Inclination towards minimally invasive genetic testing is likely to increase owing to advantages offered such as early detection, painless procedure and minimum amount of time needed for deriving necessary results.

Request for a sample of this research report @ https://www.gminsights.com/request-sample/detail/1906

Rise in number of consanguineous relations across the developing nations of Asia and Middle East will increase the demand for the use of prenatal and newborn genetic testing to diagnose the probabilities of birth defect. The rising consanguinity rates could result in genetic disorders and autosomal recessive diseases. The rising consanguineous populations arising from cousin marriages are resulting in higher inbreeding offspring. Hence, upsurge in cases of live births with genetic abnormalities is likely to increase the use of prenatal and new-born genetic testing.

Prominent Players:

Some of the leading players include Ariosa Diagnostics (Roche), Berry Genomics, BGI, Biorad, Illumina, Laboratory Corporation of America, Natera, Qiagen, Sequenom, Trivitron Healthcare and Verinata health. The firms have implemented strategic decisions that include new product launches in the field of prenatal testing. New product launches and new product development in the field of non-invasive prenatal testing along with merger and acquisitions have helped the companies increase their capabilities and sustain in the market by providing better solutions to pharmaceutical industry.

Make an inquiry for purchasing this report @ https://www.gminsights.com/inquiry-before-buying/1906

Regional Analysis:

The pervasiveness of genetic diseases such as galactosemia, phenylketonuria and severe combined immune deficiency (SCID) in the U.S. will mark the growth of market. Genetic diseases are the major reason for infant mortality in U.S. accounting for around 20% of total annual infant deaths. The mandatory newborn screening programs initiated by the government with screening coverage up to 99% coupled with provision of healthcare insurance coverage will be a major boost to the prenatal and newborn genetic testing market.

In APAC Prenatal and new-born genetic testing market, the use of genetic testing in Japan is increasing owing to rise in the number of infants born with disability and genetic defects. The permission granted by Japan Society of Obstetrics and Gynaecology to a number of medical institutions and uncertified medical facilities to conduct infant genetic testing will increase the amount of prenatal and newborn genetic screening thus by augmenting the business growth in Japan in the future.

Chapter 3. Prenatal and New-born Genetic Testing Market Industry Insights

3.1. Industry segmentation

3.2. Industry landscape, 2013 – 2024

3.3. Industry impact forces

3.3.1.  Growth drivers

3.3.1.1. Technological advancements and increasing benefits in the field of prenatal testing and newborn genetic screening in North America

3.3.1.2.    Increasing prevalence of genetic disorders and chromosomal abnormalities in Europe

3.3.1.3.    Rising consanguineous relations in countries of APAC and Middle east and Africa

3.3.1.4.    Government initiatives and support for prenatal testing and newborn genetic screening in Asia-Pacific

3.3.1.5.    Rise in adoption of Noninvasive Prenatal Testing in Latin America

3.3.2.  Industry pitfalls & challenges

3.3.2.1. Increasing false results for prenatal tests in Europe

3.3.2.2.    Lack of advanced infrastructure and skilled labor in developing region of Latin America and Asia-Pacific

3.3.2.3.    Ethical issues to prenatal testing and newborn genetic screening in Asia-Pacific and Middle East and Africa

3.4. Growth potential analysis

3.4.1.  By technology

3.4.2.  By disease

3.4.3.  By end-use

3.5. Regulatory landscape

3.5.1.  U.S

3.5.2.  Europe

3.6. Porter’s analysis

3.7. Competitive landscape, 2017

3.7.1.  Business overview

3.7.2.  Revenue analysis

3.7.3.  Product landscape

3.7.4.  Strategy dashboard

3.8. PESTEL analysis

Browse Full Report Details @ https://www.gminsights.com/industry-analysis/prenatal-and-newborn-genetic-testing-market

Global Market Insights Inc. is a global market research and management consulting company catering to leading corporations, non-profit organizations, universities and government institutions. Our main goal is to assist and partner organizations to make lasting strategic improvements and realize growth targets. Our industry research reports are designed to provide granular quantitative information, combined with key industry insights, aimed at assisting sustainable organizational development.

Global Market Insights, Inc.
4 North Main Street
Selbyville, Delaware 19975 USA
Phone: 1-302-846-7766
Toll Free: 1-888-689-0688
Email:sales@gminsights.com

This release was published on openPR.